GlassScriptPhysician profile
Kiera Ann Quinn
NPI 1144830977
$1,194.10
in general payments reported to CMS, 2019-2025
23 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.84 · 2022: $51.17 · 2023: $454 · 2024: $348 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $280.25 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $229.76 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $99.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $81.30 | 2021-2023 | Breztri |
| Idorsia Pharmaceuticals US INC | $60.02 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.97 | 2022-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $47.24 | 2024-2025 | |
| Amgen INC. | $35.70 | 2023-2024 | Evenity, Prolia |
| Daiichi Sankyo INC. | $30.96 | 2023-2024 | Injectafer |
| Abiomed | $30.51 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.79 | 2023 | Trintellix |
| Exact Sciences Corporation | $23.14 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $20.64 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.37 | 2023 | Evkeeza |
| Eisai INC. | $18.92 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.44 | 2025 | |
| Grifols USA, LLC | $18.28 | 2025 | Prolastin-C Liquid |
| Insulet Corporation | $17.14 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $16.25 | 2023 | Keveyis |
| Phadia US INC. | $15.45 | 2024 | Immunocap |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
| Merck Sharp & Dohme LLC | $14.80 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Edwards Lifesciences Corporation | $13.53 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiera Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.